Cognitive impairment in multiple sclerosis (Q28270988)

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

PubMed

volume

12

0 references

issue

5

0 references

page(s)

618-27

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years

20 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

20 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Cognitive and motor functioning in patients with multiple sclerosis: Neuropsychological predictors of walking speed and falls

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Increased functional connectivity indicates the severity of cognitive impairment in multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Risk factors for and management of cognitive dysfunction in multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Cognitive Functioning in Multiple Sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Cognitive function and quality of life in multiple sclerosis patients: a cross-sectional study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Memantine induces reversible neurologic impairment in patients with MS.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Minimal neuropsychological assessment of MS patients: a consensus approach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Social cognition and Theory of Mind in patients with relapsing-remitting multiple sclerosis

2 June 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Cognitively preserved MS patients demonstrate functional differences in processing neutral and emotional faces

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Natalizumab may improve cognition and mood in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Memory decline evolves independently of disease activity in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Assessment of cognition using the Rao's Brief Repeatable Battery of Neuropsychological Tests on a group of Brazilian patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Verbal episodic memory in 426 multiple sclerosis patients: impairment in encoding, retrieval or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Cognitive deterioration in patients with early multiple sclerosis: a 5-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Cognitive function in radiologically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Association of MRI metrics and cognitive impairment in radiologically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Diffusion tensor MRI tractography and cognitive impairment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Efficacy of an executive function intervention programme in MS: a placebo-controlled and pseudo-randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

L-amphetamine improves memory in MS patients with objective memory impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Donepezil improved memory in multiple sclerosis in a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Physical Activity and Cognitive Function in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Randomized controlled trial of yoga and exercise in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11910-012-0294-3

A randomized controlled trial of a cognitive rehabilitation intervention for persons with multiple sclerosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4581520

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22791241

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22791241